Interferon-γ inhibits experimental renal fibrosis

Slides:

Advertisements

Similar presentations

Volume 68, Issue 3, Pages (September 2005)

Advertisements

Volume 76, Issue 1, Pages (July 2009)

Volume 66, Issue 3, Pages (September 2004)

Volume 70, Issue 2, Pages (July 2006)

Volume 61, Issue 4, Pages (April 2002)

Volume 67, Issue 3, Pages (March 2005)

Volume 67, Issue 5, Pages (May 2005)

Volume 64, Issue 2, Pages (August 2003)

Volume 58, Issue 6, Pages (December 2000)

Volume 91, Issue 5, Pages (May 2017)

Pentoxifylline protects against loss of function and renal interstitial fibrosis in chronic experimental partial ureteral obstruction Hongbao Ma, Steven.

Volume 62, Issue 1, Pages (July 2002)

Volume 66, Issue 5, Pages (November 2004)

Volume 57, Issue 6, Pages (June 2000)

Volume 59, Issue 4, Pages (April 2001)

Volume 54, Issue 6, Pages (January 1998)

Volume 59, Issue 4, Pages (April 2001)

Volume 56, Issue 3, Pages (September 1999)

Hiroyuki Yanagisawa, Nobuyuki Yamazaki, Gen Sato, Osamu Wada

Karl A. Nath, Anthony J. Croatt, Jill J. Haggard, Joseph P. Grande

Volume 58, Issue 1, Pages (July 2000)

Volume 70, Issue 2, Pages (July 2006)

Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy Shinya Mizuno, Kunio Matsumoto, Toshikazu Nakamura

Mohammed S. Razzaque, Ph.D., Takashi Taguchi Kidney International

Volume 62, Issue 4, Pages (October 2002)

Volume 76, Issue 4, Pages (August 2009)

Volume 57, Issue 3, Pages (March 2000)

Inhibition of nuclear factor-κB activation reduces cortical tubulointerstitial injury in proteinuric rats Gopala K. Rangan, Yiping Wang, Yuet-Ching Tay,

Isotretinoin alleviates renal damage in rat chronic glomerulonephritis

Volume 64, Issue 4, Pages (October 2003)

Volume 70, Issue 11, Pages (December 2006)

Volume 54, Issue 5, Pages (November 1998)

Volume 62, Issue 3, Pages (September 2002)

Volume 60, Issue 1, Pages (July 2001)

Volume 63, Issue 6, Pages (June 2003)

Volume 63, Issue 6, Pages (June 2003)

Volume 79, Issue 4, Pages (February 2011)

Volume 76, Issue 5, Pages (September 2009)

Caspase-3 and apoptosis in experimental chronic renal scarring

Volume 55, Issue 1, Pages (January 1999)

Volume 63, Issue 1, Pages (January 2003)

Volume 67, Issue 2, Pages (February 2005)

C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis Gopala K. Rangan, Jeffrey W. Pippin, William.

Volume 66, Issue 4, Pages (October 2004)

Volume 71, Issue 9, Pages (May 2007)

Volume 69, Issue 12, Pages (June 2006)

M.-J. Wu, M.-C. Wen, Y.-T. Chiu, Y.-Y. Chiou, K.-H. Shu, M.-J. Tang

Volume 67, Issue 6, Pages (June 2005)

Volume 55, Issue 3, Pages (March 1999)

Volume 65, Issue 6, Pages (June 2004)

Robert L. Chevalier, Barbara A. Thornhill, Alice Y. Chang

Volume 69, Issue 10, Pages (May 2006)

The global challenge of chronic kidney disease

Volume 54, Issue 1, Pages (July 1998)

Volume 60, Issue 5, Pages (November 2001)

Volume 62, Issue 3, Pages (September 2002)

Volume 69, Issue 7, Pages (April 2006)

Collagen accumulation is reduced with UK

Volume 58, Issue 3, Pages (September 2000)

Volume 60, Issue 5, Pages (November 2001)

The course of the remnant kidney model in mice

Volume 58, Issue 4, Pages (October 2000)

Volume 56, Issue 6, Pages (December 1999)

Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes Guorong Ma, Terri J. Allen, Mark E. Cooper,

Volume 70, Issue 3, Pages (August 2006)

Effect of prenatal dexamethasone on rat renal development

T-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis Masashi Haraguchi, Wayne A. Border, Yufeng Huang,

Volume 62, Issue 3, Pages (September 2002)

Volume 61, Issue 6, Pages (June 2002)

Volume 65, Issue 1, Pages (January 2004)

Presentation transcript:

Interferon-γ inhibits experimental renal fibrosis Simon D. Oldroyd, Graham L. Thomas, Giulio Gabbiani, A. Meguid El Nahas Kidney International Volume 56, Issue 6, Pages 2116-2127 (December 1999) DOI: 10.1046/j.1523-1755.1999.00775.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 Photographs showing (A) the drug delivery system of osmotic minipump and fenestrated cannula and (B) close up of the cannula showing fenestrations. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 Distribution of 125I-IFN-γ following intrarenal administration from a one-day Alzet® osmotic minipump. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 3 Immunolocalization of rat recombinant IFN-γ throughout kidneys from (A) saline vehicle-treated SNx rats and (B) rat recombinant IFN-γ–treated SNx rats following one week of administration. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 4 Histogram showing (A) creatinine clearance and (B) urinary protein in rats of groups 1 through 3 following SNx.*P < 0.05, **P < 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (□) sham operated; (■) group 1; () group 2; () group 3. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 4 Histogram showing (A) creatinine clearance and (B) urinary protein in rats of groups 1 through 3 following SNx.*P < 0.05, **P < 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (□) sham operated; (■) group 1; () group 2; () group 3. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 4 Histogram showing (A) creatinine clearance and (B) urinary protein in rats of groups 1 through 3 following SNx.*P < 0.05, **P < 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (□) sham operated; (■) group 1; () group 2; () group 3. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 5 Histogram showing (A) glomerulosclerosis and (B) tubulointerstitial fibrosis in rats of groups 1 through 3 following SNx.*P < 0.05, **P < 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (□) sham operated; (■) group 1; () group 2; () group 3. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 5 Histogram showing (A) glomerulosclerosis and (B) tubulointerstitial fibrosis in rats of groups 1 through 3 following SNx.*P < 0.05, **P < 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (□) sham operated; (■) group 1; () group 2; () group 3. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 5 Histogram showing (A) glomerulosclerosis and (B) tubulointerstitial fibrosis in rats of groups 1 through 3 following SNx.*P < 0.05, **P < 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (□) sham operated; (■) group 1; () group 2; () group 3. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 6 Photomicrographs of representative fields of immunolocalization of α-smooth muscle actin in day 45 group 2 animals (A and B) and day 45 group 3 animals (C and D). Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 7 Histogram showing the changes in α-SMA staining in the three groups throughout the experimental time course. (A) in glomeruli and (B) in tubulointerstitium. *P < 0.05; **P < 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (□) sham operated; (■) group 1; () group 2; () group 3. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 7 Histogram showing the changes in α-SMA staining in the three groups throughout the experimental time course. (A) in glomeruli and (B) in tubulointerstitium. *P < 0.05; **P < 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (□) sham operated; (■) group 1; () group 2; () group 3. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 7 Histogram showing the changes in α-SMA staining in the three groups throughout the experimental time course. (A) in glomeruli and (B) in tubulointerstitium. *P < 0.05; **P < 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (□) sham operated; (■) group 1; () group 2; () group 3. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 8 Photomicrographs of representative fields of immunolocalization of ED-1 in group 2 animals. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 9 Photomicrographs of representative fields of immunolocalization of collagen III in group 3 animals (A), group 1 animals (B), group 2 animals (C and D) at day 45, and collagen IV in group 3 animals (E) and group 1 (F) at day 30. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 10 Histogram showing the changes in collagen III (A) and collagen IV (B) staining in the three groups throughout the experimental time course.*P < 0.05, **P < 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (□) sham operated; (■) group 1; () group 2; () group 3. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 10 Histogram showing the changes in collagen III (A) and collagen IV (B) staining in the three groups throughout the experimental time course.*P < 0.05, **P < 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (□) sham operated; (■) group 1; () group 2; () group 3. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 10 Histogram showing the changes in collagen III (A) and collagen IV (B) staining in the three groups throughout the experimental time course.*P < 0.05, **P < 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (□) sham operated; (■) group 1; () group 2; () group 3. Kidney International 1999 56, 2116-2127DOI: (10.1046/j.1523-1755.1999.00775.x) Copyright © 1999 International Society of Nephrology Terms and Conditions